Selank: Anxiolytic Nootropic Peptide Research and Regulatory Outlook

Almost everything published on Selank was written by the people who invented it. It was built by Russian state-funded institutions, tested mostly in Russia, and its human evidence sits almost entirely outside the Western peer-reviewed literature. That single fact shapes how scientists read it and how regulators treat it. Start there, because the rest of the story doesn’t make sense without it.

What Selank is

Selank is a synthetic seven-amino-acid peptide built from tuftsin (Thr-Lys-Pro-Arg), a small natural peptide that comes off immunoglobulin G and has a role in immune signalling plus some described neurological effects. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. The modification makes tuftsin last longer and changes how it hits its receptors.

Russian pharmacology classifies it as an anxiolytic: it appears to dial down anxiety without the sedation or dependence that come with benzodiazepines. It’s also been studied for cognitive effects, with Russian researchers reporting better attention and memory on task. It’s a registered drug in Russia, sold under the name Selank, available through pharmacies there for anxiety. Registered as a drug in one country isn’t the same as proven to a Western regulator’s standard, which is the whole tension here.

What the literature actually shows

Read the literature with one thing in mind: most of it came from research groups tied to the compound’s development. That’s a publication-bias risk and it’s why independent replication barely exists.

In animals, Selank shifts central neurotransmitter systems, with effects on serotonin, GABA, and dopamine pathways depending on the model. A 2009 paper in Experimental and Clinical Pharmacology compared Selank against tuftsin for serotonin metabolism in PCPA-treated rats. In rats. In labs.

Human studies exist, with caveats attached. Russian clinical pharmacology journals, including a 2014 paper in the S.S. Korsakov journal of neurology and psychiatry that compared Selank against phenazepam in patients with anxiety disorders, reported comparable anxiolytic effects with different tolerability. These were generally small, run in one country, and not consistently replicated. The methodology and risk-of-bias quality for many of them wouldn’t clear the bar for regulatory approval in the US or EU.

There are no published Phase II or Phase III trials of Selank in a Western regulatory context. It hasn’t been submitted to the FDA, EMA, or any equivalent agency. Proposed, not settled.

Where Selank sits with regulators

Selank’s US position is unsettled. It’s not on the FDA’s 503A or 503B bulk substances lists. It’s not a controlled substance under the DEA’s Controlled Substances Act.

Here’s the part people get wrong: Selank is not on the PCAC July 23–24, 2026 review agenda. The Federal Register notice listing nominated bulk substances doesn’t include it. When and whether Selank reaches a future PCAC review hasn’t been announced — the July 2026 event won’t resolve its US status, and the next step isn’t on the public calendar.

For athletes under anti-doping rules: Selank doesn’t appear by literal name on the WADA 2026 Prohibited List, but it falls under S0 — non-approved substances — because it isn’t an approved therapeutic anywhere outside Russia. S0 is prohibited at all times, in and out of competition. Don’t read the missing literal name as permission.

Where the evidence runs out

Selank’s evidence gaps are among the widest in this series, and it’s the same root cause every time: the data sits in one national research ecosystem with no independent replication.

Independent validation of the human findings is largely missing. The Russian anxiolytic data hasn’t been reproduced in Western academic or regulatory settings. Whether it would survive that scrutiny isn’t known.

The mechanism isn’t pinned down. The proposed effects on serotonin, dopamine, GABA, and enkephalin systems have been studied in animals, but the specific receptor interactions and downstream pathways in humans aren’t well-characterised.

Long-term safety hasn’t been systematically studied in any context Western researchers can access. The Russian approval covers a defined therapeutic use; chronic-use safety data in healthy people just isn’t there.

And a future PCAC review, whenever it lands, wouldn’t answer whether Selank works. It would only decide whether the FDA considers it eligible for 503A compounding under a physician.

The honest verdict on Selank

Selank has a plausible anxiolytic mechanism and a human evidence base that’s real but comes almost entirely from one research ecosystem with no independent Western replication. It is absent from the July 2026 PCAC docket, and no future PCAC review that would include it has been announced.

The honest framing: non-replicated human data plus no scheduled US regulatory review makes Selank one of the most uncertain compounds in this set. Watch the Federal Register for the next PCAC notice, whenever it lands.